MicroRNA-31 Regulates Chemosensitivity in Malignant Pleural Mesothelioma

September 19, 2017

Molecular Therapy. Nucleic Acids 2017 September [Epub 2017 July 8] [Link] Moody HL, Lind MJ, Maher SG Asbstract Malignant pleural mesothelioma (MPM) is associated with an extremely poor prognosis, and most patients initially are or rapidly become unresponsive to platinum-based chemotherapy. MicroRNA-31 (miR-31) is encoded on a genomic fragile site, 9p21.3, which is reportedly lost…

Read More

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study

September 19, 2017

The Lancet. Oncology 2017 September [Epub ahead of print] [Link] van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, Cooper WA, Kritharides L, Ridley L, Pattison ST, MacDiarmid J, Brahmbhatt H, Reid G Abstract BACKGROUND: TargomiRs are minicells (EnGeneIC Dream Vectors) loaded with…

Read More

Clinical staging of malignant pleural mesothelioma: current perspectives

September 7, 2017

Lung Cancer 2017 August [Link] Bonomi M, De Filippis C, Lopci E, Gianoncelli L, Rizzardi G, Cerchiaro E, Bortolotti L, Zanello A, Ceresoli G Abstract Malignant pleural mesothelioma (MPM) is a disease with limited therapeutic options, the management of which is still controversial. Diagnosis is usually made by thoracoscopy, which allows multiple biopsies with histological…

Read More

Regulation of microRNA using promising dietary phytochemicals: Possible preventive and treatment option of malignant mesothelioma

September 2, 2017

Biomedicine & Pharmacotherapy 2017 August [Epub ahead of print] [Link] Sayeed MA, Bracci M, Lucarini G, Lazzarini R, Di Primio R, Santarelli L Abstract Malignant mesothelioma (MM) is a very aggressive, lethal cancer, and its incidence is increasing worldwide. Development of multi-drug resistance, therapy related side-effects, and disease recurrence after therapy are the major problems…

Read More

MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study

August 12, 2017

Disease Markers 2017 [Epub July 3] [Link] Mozzoni P, Ampollini L, Goldoni M, Alinovi R, Tiseo M, Gnetti L, Carbognani P, Rusca M, Mutti A, Percesepe A, Corradi Abstract BACKGROUND: The identification of diagnostic/prognostic biomarkers for asbestos-related diseases is relevant for early diagnosis and patient survival and may contribute to understanding the molecular mechanisms underlying…

Read More

Targeting eukaryotic protein translation in mesothelioma

July 22, 2017

Translational Lung Cancer Research 2017 June [Link] Kratzke RA Abstract The default mechanism for protein translation in eukaryotes involves activation of the eIF4 complex at the 5′ end of mRNA. This activity is upregulated in cancers, resulting in the expression of a variety of proteins necessary for the development and maintenance of the neoplastic state.…

Read More

Tumor suppressor candidate 2 (TUSC2, FUS-1) and human cancers

July 18, 2017

Discovery Medicine 2017 May [Link Rimkus T, Sirkisoon S, Harrison A, Lo HW Abstract Tumor suppressor candidate 2 (TUSC2, also known as FUS1) was identified in 2000 as a candidate tumor suppressor gene located in a region on chromosome 3p21.3 that is homozygously deleted in some lung and breast cancers. The deletion is rare in…

Read More

Targeting YAP in malignant pleural mesothelioma

May 10, 2017

Journal of Cellular and Molecular Medicine 2017 Ma 4 [Epub ahead of print] [Link] Zhang WQ, Dai YY, Hsu PC, Wang H, Cheng L, Yang YL, Wang YC, Xu ZD, Liu S, Chan G, Hu B, Li H, Jablons DM, You L Abstract Malignant mesothelioma is an aggressive cancer that is resistant to current therapy.…

Read More